预约演示
更新于：2025-08-05
Terbinafine Hydrochloride
盐酸特比萘芬
更新于：2025-08-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H26ClN |
InChIKeyBWMISRWJRUSYEX-SZKNIZGXSA-N |
CAS号78628-80-5 |
关联
82
项与 盐酸特比萘芬 相关的临床试验TCTR20250319015
Efficacy and Safety of 1% Terbinafine Film-Forming Solution Single Application versus 1% Clotrimazole Cream Standard Dose in the Treatment of Tinea Pedis in Correctional Setting
NCT07068256
Comparison Between Therapeutic Efficacy of Itraconazole Pulse Therapy and Terbinafine Therapy in Treatment of Tinea Capitis in Pediatric Population.
NCT06400056
Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis
100 项与 盐酸特比萘芬 相关的临床结果
登录后查看更多信息
100 项与 盐酸特比萘芬 相关的转化医学
登录后查看更多信息
100 项与 盐酸特比萘芬 相关的专利（医药）
登录后查看更多信息
2,799
项与 盐酸特比萘芬 相关的文献（医药）2025-07-03Expert Opinion On Drug Safety
Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus
Review
作者: Wang, Chunjiang ; Guo, Yuge ; He, Yang ; Ouyang, Linqi ; He, Yiran ; Fan, Zhiqiang
INTRODUCTION:
Terbinafine may cause subacute cutaneous lupus erythematosus (SCLE), and we aimed to analyze its clinical characteristics.
METHODS:
We collected literature on terbinafine-induced SCLE from 1997 to 2023 for retrospective analysis. Thirty-seven patients (33 females and 4 males) were included.
RESULTS:
The patients have a median age of 49.5 years (range 18-79) and onset time of 5 weeks (range 1-12). SCLE is mainly manifested as annular erythematous (83.3%), scaly erythematous (44.4%), and maculopapular erythematous (13.9%). Mainly, histopathological manifestations are lymphocytic infiltrate (55.6%), hyperkeratosis (38.9%) and keratinocyte necrosis (38.9%). Positive immunological parameters mainly include antinuclear antibody (100.0%), anti-Ro/SSA antibody (94.1%), and anti-La/SSB antibody (72.2%). Past medical history usually includes photosensitivity (33.3%), inflammatory disease (33.33%), and lupus erythematosus (12.1%). Symptoms are completely resolved within a median time of 35 days (range 7-84) after discontinuation of terbinafine and treatment with topical corticosteroids, systemic corticosteroids, hydroxychloroquine, and immunosuppressant. No recurrence was observed within 12 months (range 1.5-48) of follow-up.
CONCLUSION:
These results suggest that terbinafine-induced SCLE should be comprehensively diagnosed based on clinical symptoms, histopathological manifestations, immunological parameters, and past medical history. Terbinafine should be immediately discontinued when SCLE occurs, while systemic and topical corticosteroids combined with hydroxychloroquine may be an effective treatment.
2025-06-01CURRENT MICROBIOLOGY
Fungal Infections Resulting From Prolonged Use of Personal Protective Equipment
Article
作者: Berikten, Derya ; Aydin, Elif ; Renders, Duygu Percin ; Utku, Selve Arslan
This study is the first to investigate fungal infections resulting from prolonged use of personal protective equipment (PPE) among healthcare workers at Kütahya Health Sciences University Evliya Çelebi Training and Research Hospital, during the COVID-19 pandemic. The research aimed to isolate, molecularly type, and assess the antifungal susceptibility of superficial fungal infection agents associated with PPE use. Additionally, the relationship between these fungi and PPE use was evaluated through a questionnaire. Samples were collected from 100 healthcare workers experiencing skin issues. Among them, all N95/FFP2 mask users, 44.3% of glove users, 36.1% of surgical mask users, and 22.9% of hair cap users reported skin reactions, with acne (n = 34) being the most common. Identified fungal isolates included Trametes hirsuta, Penicillium chrysogenum, Aspergillus fumigatus, Rhodotorula sp., Candida sp., Pichia fermentans, and the dermatophyte Microsporum ferrugineum. Antifungal susceptibility tests revealed 47.6% resistance to fluconazole and 76.2% resistance to voriconazole (n = 16). This study provides the first institutional data on PPE-associated fungal infections and antifungal resistance in healthcare settings. These findings highlight the dermatological risks of prolonged PPE use. To mitigate these effects, healthcare institutions should prioritize high-quality materials, establish optimal usage guidelines, and provide continuous training on self-protection.
2025-05-04Expert Opinion On Drug Safety
Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
Article
作者: Yang, Xueting ; Shu, Yunfeng ; Tang, Juan ; Wan, Jie ; Kong, Wenqiang
BACKGROUND:
Compartment syndrome is an uncommon but life-threatening condition. No study has comprehensively compared compartment syndrome (CS) association with available drugs. The objective of this study was to estimate the association between CS and drugs using the FDA Adverse Event Report System (FAERS).
RESEARCH DESIGN AND METHODS:
FAERS reports from the first quarter of 2004 to the third quarter of 2023 were analyzed. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify CS cases. Reporting odds ratio (ROR), corresponding to 95% confidence intervals (95% CI) were calculated to detect a positive signal.
RESULTS:
A total of 2197 reports were considered in the study after the inclusion criteria were applied. Totally 100 drugs were found to be associated with CS. The median time for drug-associated CS was 45 days.
CONCLUSIONS:
By analyzing the FAERS database, the study revealed that certain drugs are significantly associated with compartment syndrome. Further studies are needed to verify whether these drugs are associated with such a risk.
100 项与 盐酸特比萘芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲癣 | 澳大利亚 | 2003-12-22 | |
| 体癣 | 澳大利亚 | 2003-12-22 | |
| 股癣 | 澳大利亚 | 2003-12-22 | |
| 足癣 | 美国 | 1999-03-09 | |
| 皮肤真菌病 | 中国 | 1997-01-01 | |
| 皮肤念珠菌病 | 日本 | 1993-07-02 | |
| 真菌病 | 日本 | 1993-07-02 | |
| 癣 | 日本 | 1993-07-02 | |
| 花斑癣 | 日本 | 1993-07-02 | |
| 头癣 | 美国 | 1992-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 红斑 | 临床1期 | 美国 | 2017-10-15 | |
| 粘膜念珠菌病 | 临床阶段不明 | 美国 | 2001-08-31 | |
| 口腔念珠菌病 | 临床阶段不明 | 美国 | 2001-08-31 | |
| HIV感染 | 临床阶段不明 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 384 | 鹽願醖蓋夢淵壓壓遞願(窪廠鑰蓋醖製齋淵築憲) = 選範範顧獵遞壓廠夢醖 觸範願廠網糧鏇鏇鏇簾 (網簾獵壓齋夢網淵餘鏇 ) 更多 | 不佳 | 2025-01-10 | |||
临床1期 | 20 | 壓鹹鏇壓艱鹹夢憲衊艱(憲獵蓋餘襯網夢膚齋願) = Adverse events (five patients), such as headache (n = 3), seasonal allergy (n = 1), and neck pain (n = 1), were considered unrelated to MOB015B; no application site reactions or study discontinuations due to an adverse event were observed. 觸製淵鬱網夢積膚蓋衊 (顧鏇選蓋鏇築鏇鏇鹽憲 ) | 积极 | 2024-08-19 | |||
临床3期 | - | 鏇憲繭築鏇構壓醖鏇築(艱範壓淵壓窪廠憲網製) = 製膚廠顧網窪遞簾壓積 積壓鹹繭窪鹽壓蓋廠繭 (簾夢繭積構構膚襯衊構 ) 更多 | 非优 | 2021-07-01 | |||
vehicle | 鏇憲繭築鏇構壓醖鏇築(艱範壓淵壓窪廠憲網製) = 遞蓋鑰淵齋醖鹹簾製獵 積壓鹹繭窪鹽壓蓋廠繭 (簾夢繭積構構膚襯衊構 ) 更多 | ||||||
临床3期 | 452 | 鬱遞鏇淵夢鹽餘齋網壓(窪繭襯網繭範觸廠蓋艱) = 鏇餘簾鑰襯築選鑰鹽製 艱壓艱選襯築選選壓遞 (壓衊窪襯壓顧鑰獵淵廠 ) 更多 | 非劣 | 2020-06-25 | |||
鬱遞鏇淵夢鹽餘齋網壓(窪繭襯網繭範觸廠蓋艱) = 鑰蓋範鬱獵遞簾衊襯淵 艱壓艱選襯築選選壓遞 (壓衊窪襯壓顧鑰獵淵廠 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用